San-Ni Chen1, Iebin Lian, Ya-Chi Hwang, Yi-Hsing Chen, Yao-Chung Chang, Kun-Hsien Lee, Chih-Chun Chuang, Wei-Chi Wu. 1. *Department of Ophthalmology, Changhua Christian Hospital, Changhua, Taiwan; †School of Medicine, Chung-Shan Medical University, Taichung, Taiwan; ‡School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; §Graduate Institute of Statistics and Information Science, National Changhua University of Education, Changhua, Taiwan; and ¶Department of Ophthalmology, Chang-Gung Memorial Hospital, and School of Medicine, Chang-Gung University, Taoyuan, Taiwan.
Abstract
PURPOSE: To compare the effect and the treatment outcomes of bevacizumab and ranibizumab in the treatment of Type 1 retinopathy of prematurity (ROP). METHODS: This was a bicentered retrospective case series performed at institutional referral centers. Seventy-two eyes of 37 patients who had intravitreal injections of either bevacizumab or ranibizumab as the primary treatment for Type 1 ROP were included. Outcomes' measures included regression and recurrence of ROP, the surgical complications, and refractive errors at a corrected age of 1 year. RESULTS: All but one eye in the bevacizumab group had retinal neovascularization and plus disease regression after anti-vascular endothelium growth factor treatment. Neither recurrence of ROP nor major ocular complications, including cataract, retinal detachment, and endophthalmitis occurred in any of the treated eyes. There were no significant differences in mean refractive errors between the patients treated with intravitreal injections of bevacizumab or ranibizumab at the corrected age of 1 year. A significantly higher chance of high myopia was noted in the bevacizumab group (P = 0.03). CONCLUSION: Both bevacizumab and ranibizumab showed similar efficacy in the regression of ROP with minor mean refractive errors at 1 year of corrected age. However, high myopia was more prevalent in the bevacizumab-treated eyes.
PURPOSE: To compare the effect and the treatment outcomes of bevacizumab and ranibizumab in the treatment of Type 1 retinopathy of prematurity (ROP). METHODS: This was a bicentered retrospective case series performed at institutional referral centers. Seventy-two eyes of 37 patients who had intravitreal injections of either bevacizumab or ranibizumab as the primary treatment for Type 1 ROP were included. Outcomes' measures included regression and recurrence of ROP, the surgical complications, and refractive errors at a corrected age of 1 year. RESULTS: All but one eye in the bevacizumab group had retinal neovascularization and plus disease regression after anti-vascular endothelium growth factor treatment. Neither recurrence of ROP nor major ocular complications, including cataract, retinal detachment, and endophthalmitis occurred in any of the treated eyes. There were no significant differences in mean refractive errors between the patients treated with intravitreal injections of bevacizumab or ranibizumab at the corrected age of 1 year. A significantly higher chance of high myopia was noted in the bevacizumab group (P = 0.03). CONCLUSION: Both bevacizumab and ranibizumab showed similar efficacy in the regression of ROP with minor mean refractive errors at 1 year of corrected age. However, high myopia was more prevalent in the bevacizumab-treated eyes.
Authors: Linda A Cernichiaro-Espinosa; Francisco J Olguin-Manriquez; Andree Henaine-Berra; Gerardo Garcia-Aguirre; Hugo Quiroz-Mercado; Maria A Martinez-Castellanos Journal: Int Ophthalmol Date: 2016-01-14 Impact factor: 2.031
Authors: Tariq Aldebasi; Muataz A Guma; Rabia Bashir; Saif Al Saif; Waleed A Altwaijri; Abdulkareem M Al Bekairy Journal: Med Princ Pract Date: 2019-04-16 Impact factor: 1.927
Authors: Christopher M Schafer; Jami M Gurley; Katarzyna Kurylowicz; Prisca K Lin; Wen Chen; Michael H Elliott; George E Davis; Faizah Bhatti; Courtney T Griffin Journal: Proc Natl Acad Sci U S A Date: 2020-10-05 Impact factor: 11.205